WEIGHT Management  & GLP-1 Peptide therapy

Peptides, including GHSs, are short chains of amino acids, which are little molecules that are the building blocks of peptides and proteins.  Peptides exist naturally in your body, but you can also find them in animal or plant sources of protein, including meat, fish, dairy, eggs, beans, lentils, and whole grains. Manufacturers can isolate these peptides or make them by combining individual amino acids.  The structure of peptides is similar to that of certain hormones or messaging compounds already present in your body. Many also have the ability to penetrate tissues.These short chains of amino acids are involved in a variety of processes in your body, including in the production of hormones and DNA. They’re also helpful when building muscle tissue.

Semaglutide is a Glucagon-like peptide-1 (GLP-1) produced by the gut. It increases insulin production, a hormone that lowers the blood sugar level while inhibiting glucagon secretion which is a hormone that raises blood sugar, reduces appetite and energy intake while delaying gastric emptying. It was first developed in 2012 by Novo Nordisk as a longer-acting option to Liraglutide. In 2017, this drug was approved as an anti-diabetic medication used to treat type 2 diabetes and obesity. In June 2021, it got approved for chronic weight management in obese individuals with a (BMI) ≥ 30 kg/m2 or overweight (initial BMI ≥ 27 kg/m2) with at least one weight-related comorbidity.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly Tirzepatide as compared with Semaglutide, a selective GLP-1 receptor agonist, are unknown.

In patients with type 2 diabetes, Tirzepatide was non-inferior and superior to Semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. See SURPASS-2 ClinicalTrials.gov number, NCT03987919.